---
title: "Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286568281.md"
description: "Stifel Nicolaus has maintained a Buy rating for Inhibrx Biosciences Inc (INBX) with a price target of $325.00. Analyst Dara Azar, noted for a 27.3% average return, follows a similar Buy rating from LifeSci Capital, which set a price target of $230.00."
datetime: "2026-05-15T12:45:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286568281.md)
  - [en](https://longbridge.com/en/news/286568281.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286568281.md)
---

# Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)

In a report released today, Dara Azar from Stifel Nicolaus reiterated a Buy rating on Inhibrx Biosciences Inc, with a price target of $325.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Azar is a 2-star analyst with an average return of 27.3% and a 66.67% success rate.

In a report released on May 11, LifeSci Capital also maintained a Buy rating on the stock with a $230.00 price target.

### Related Stocks

- [INBX.US](https://longbridge.com/en/quote/INBX.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)

## Related News & Research

- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | LIMN Stock News](https://longbridge.com/en/news/287218720.md)